LSU Health Digital Scholar (Louisiana State Univ.)
Not a member yet
8182 research outputs found
Sort by
Alert to Action: Implementing Artificial Intelligence-Driven Clinical Decision Support Tools for Sepsis
Get PDFImproving Hepatitis A and B Vaccination Rates in Adults with Hepatitis C and Chronic Liver Disease in an Internal Medicine Residents Clinic
Get PDF
Enhancing Colorectal Cancer Screening Awareness in a Primary Care Clinic through Visual Aids and Posters: A Quality Improvement Initiative
Get PDFLSU Health Sciences Center 152nd Commencement, May 2025
Get PDFThe program for the 152nd Commencement of LSU Health Sciences Center - New Orleans held May 15, 2025.https://digitalscholar.lsuhsc.edu/lsuhscnopub_gradprog/1165/thumbnail.jp
Enhancing hemostasis potency in hemophilia with a small interfering RNA targeting protein S
No full textBACKGROUND: One hemophilia treatment concept focuses on rebalancing coagulation and anticoagulation to restore normal blood clotting. Targeting the coagulation regulator, protein S (PS), in hemophilia shows promise to increase the generation of thrombin-a critical enzyme in the clotting process. OBJECTIVES: This study aimed to: (1) assess whether inhibiting PS increases thrombin generation (TG) in plasma from individuals with hemophilia A (HA) and B (HB); and (2) develop a hepatocyte-targeted PS-silencing RNA (siRNA) therapy using N-acetylgalactosamine (GalNAc) conjugation to restore hemostasis in hemophilia without increasing thromboembolic risks. METHODS: We assessed TG in plasma from patients with HA and HB. To target the liver specifically, we developed a PS-siRNA conjugated with GalNAc. This approach ensures that PS levels remain adequate in other cells, thereby minimizing the risk of thrombosis. Additionally, we evaluated the therapeutic potential of PS-siRNA in preclinical models. RESULTS: Inhibiting PS with a polyclonal antibody in plasma resulted in a 3-5 fold increase in TG in HA and a 4-9 fold increase in HB plasma, with a 70% reduction in plasma PS. In preclinical models, subcutaneous PS-siRNA therapy in HA mice and non-human primates successfully lowered PS levels and improved clot formation. It also prevented bleeding in both saphenous vein puncture and knee-injury models in HA mice. Notably, it enhanced clotting without triggering widespread clot formation. CONCLUSIONS: Reducing PS levels enhances TG in hemophilia models, and PS-siRNA therapy shows promise in improving hemostasis. This approach warrants further clinical investigation as a potential treatment for hemophilia
Alcohol Exposure Among Patients With Dilated Cardiomyopathy and Their First-Degree Relatives: The DCM Precision Medicine Study
No full textBACKGROUND: Whether prolonged and excessive alcohol consumption contributes to dilated cardiomyopathy (DCM) remains uncertain. This study aimed to describe the prevalence of alcohol use in patients with DCM and their first-degree relatives (FDRs) and determine if cumulative alcohol exposure associates with DCM/partial DCM or modifies the association of DCM with DCM-relevant rare variants. METHODS: All probands had DCM; FDRs were classified as with or without DCM or partial DCM. Alcohol exposure was measured with the Alcohol Use Disorder Identification Test-Consumption questionnaire and years of drinking. Rare variants in 36 DCM genes were classified as pathogenic, likely pathogenic, or variants of uncertain significance (pathogenic, likely pathogenic, variant of uncertain significance). Generalized linear mixed models were used to assess the association of DCM/partial DCM with alcohol use among FDRs. RESULTS: DCM/partial DCM was found in 21.8% of 1373 FDRs of 1148 DCM probands. The prevalence of former or current alcohol use was 68% for probands and 70% for FDRs. About 30% of probands and 37% of FDRs had positive Alcohol Use Disorder Identification Test-Consumption scores, indicating moderate or heavy drinking. Among FDRs, DCM/partial DCM was associated with the presence of pathogenic/likely pathogenic variants in DCM genes (odds ratio, 3.51 [95% CI, 2.33-5.29]) but not with alcohol exposure. Cumulative alcohol exposure was not found to modify the association between DCM/partial DCM and these variants (P=0.55). CONCLUSIONS: Alcohol use was frequent among probands and FDRs. This study did not provide evidence supporting an association of cumulative alcohol exposure with DCM/partial DCM or a modifying effect of alcohol use on the association of DCM with DCM-relevant rare variants. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03037632
Reduced Major Adverse Cardiovascular Events (MACE) with Interleukin-17 Inhibitors Compared to Methotrexate in Psoriasis Patients: A multi-center retrospective cohort analysis
No full textHematopoietic Cell Transplantation for Wiskott-Aldrich Syndrome - Impact of Age, Donor, and Infection: A Pidtc Report
No full textThe 2025 Tandem Meetings of ASTCT and CIBMTR, February 12 - 15, 2025 Honolulu, H